Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Pfizer Inc. is conducting a study titled ‘Korean Post-marketing Surveillance for Prevenar 20’ to assess the safety of Prevenar 20, a Pneumococcal 20-valent conjugate vaccine, in the Korean market. The study aims to monitor the vaccine’s safety among participants aged 6 weeks and older, providing critical insights into its post-market performance.
Intervention/Treatment: The intervention being tested is the Pneumococcal 20-valent conjugate vaccine, known as Prevenar 20. This biological treatment is administered intramuscularly, primarily in the shoulder muscle, to prevent pneumococcal infections.
Study Design: This is an observational cohort study with a prospective time perspective. All participants will receive the Prevenar 20 vaccine, and their safety data will be collected over a 28-day period through clinic visits or remote communication.
Study Timeline: The study is not yet recruiting, with the initial submission date on December 29, 2024, and the last update on September 5, 2025. These dates are crucial as they mark the study’s progress and readiness to begin participant enrollment.
Market Implications: The successful completion of this study could bolster Pfizer’s market position by reinforcing the safety profile of Prevenar 20, potentially boosting investor confidence. As the vaccine enters the Korean market, it may influence Pfizer’s stock performance positively, especially if safety outcomes are favorable compared to competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.